Nur Nicholson Sells 3,948 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) insider Nur Nicholson sold 3,948 shares of the stock in a transaction on Wednesday, January 22nd. The stock was sold at an average price of $30.43, for a total value of $120,137.64. Following the completion of the sale, the insider now directly owns 84,489 shares in the company, valued at approximately $2,571,000.27. This represents a 4.46 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Nur Nicholson also recently made the following trade(s):

• On Friday, January 17th, Nur Nicholson sold 2,145 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $29.96, for a total value of $64,264.20.

Apellis Pharmaceuticals Trading Down 2.5 %

Shares of NASDAQ:APLS opened at $30.00 on Friday. The stock has a market capitalization of $3.73 billion, a price-to-earnings ratio of -14.78 and a beta of 0.94. The company has a debt-to-equity ratio of 1.91, a quick ratio of 3.73 and a current ratio of 4.36. The stock’s 50-day simple moving average is $32.08 and its two-hundred day simple moving average is $33.18. Apellis Pharmaceuticals, Inc. has a 52-week low of $24.34 and a 52-week high of $71.90.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its earnings results on Tuesday, November 5th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.14). Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The firm had revenue of $196.83 million during the quarter, compared to analysts’ expectations of $200.00 million. During the same period in the previous year, the business posted ($1.17) earnings per share. The company’s revenue for the quarter was up 78.3% on a year-over-year basis. Analysts expect that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on APLS. Oppenheimer cut their target price on Apellis Pharmaceuticals from $65.00 to $40.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 6th. Robert W. Baird cut their target price on Apellis Pharmaceuticals from $92.00 to $55.00 and set an “outperform” rating on the stock in a research note on Thursday, November 7th. Mizuho cut their target price on Apellis Pharmaceuticals from $39.00 to $38.00 and set a “neutral” rating on the stock in a research note on Thursday, October 24th. Royal Bank of Canada reissued a “sector perform” rating and issued a $26.00 target price on shares of Apellis Pharmaceuticals in a research note on Tuesday. Finally, Citigroup dropped their price objective on Apellis Pharmaceuticals from $63.00 to $51.00 and set a “buy” rating on the stock in a research report on Wednesday, November 6th. Eight equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $46.71.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. raised its stake in shares of Apellis Pharmaceuticals by 23.3% in the third quarter. JPMorgan Chase & Co. now owns 3,884,730 shares of the company’s stock worth $112,036,000 after buying an additional 735,160 shares during the period. Braidwell LP grew its holdings in Apellis Pharmaceuticals by 410.8% during the 3rd quarter. Braidwell LP now owns 3,125,183 shares of the company’s stock valued at $90,130,000 after buying an additional 2,513,383 shares in the last quarter. Jennison Associates LLC grew its holdings in Apellis Pharmaceuticals by 51.6% during the 4th quarter. Jennison Associates LLC now owns 2,760,404 shares of the company’s stock valued at $88,084,000 after buying an additional 939,289 shares in the last quarter. Assenagon Asset Management S.A. grew its holdings in Apellis Pharmaceuticals by 191.9% during the 3rd quarter. Assenagon Asset Management S.A. now owns 2,144,415 shares of the company’s stock valued at $61,845,000 after buying an additional 1,409,707 shares in the last quarter. Finally, Geode Capital Management LLC grew its holdings in Apellis Pharmaceuticals by 1.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,810,526 shares of the company’s stock valued at $52,229,000 after buying an additional 22,609 shares in the last quarter. Institutional investors own 96.29% of the company’s stock.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).